Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ICU Medical (ICUI)

ICU Medical Q4 revenue rises to $587.9 million; GAAP net loss widens

Mixed Impact 3 of 5 earnings Written later

ICU Medical reported fourth quarter 2023 revenue of $587.9 million, up from $578.0 million a year earlier, but its GAAP net loss widened to $(17.1) million, or $(0.71) per diluted share, from $(15.5) million, or $(0.65), in the prior-year quarter. Adjusted diluted EPS was $1.57 versus $1.60, and adjusted EBITDA was $86.3 million versus $96.4 million, so higher sales did not translate into higher profit on either measure. The company also issued fiscal 2024 guidance calling for a GAAP net loss of $(88) million to $(71) million and adjusted EBITDA of $330 million to $370 million.

Key points

  • Q4 2023 revenue was $587.9 million versus $578.0 million; GAAP gross margin was 29% versus 30%.
  • GAAP net loss was $(17.1) million, or $(0.71) per diluted share, versus $(15.5) million, or $(0.65), a year earlier.
  • Adjusted diluted EPS was $1.57 versus $1.60; adjusted EBITDA was $86.3 million versus $96.4 million.
  • Fiscal 2024 guidance: GAAP net loss of $(88) million to $(71) million; adjusted diluted EPS of $4.40 to $5.10.

The filing

CompanyICU Medical (ICUI)
Form8-K, current report
Filed with the SECFeb 27, 2024, 4:11 PM ET
Accession number0000883984-24-000004

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:01 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 27, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.